NYSEARCA:LDRS

Innovator IBD ETF Leaders ETF Stock Forecast, Price & News

$28.27
0.00 (0.00 %)
(As of 08/13/2021)
Add
Today's Range
$28.24
$28.27
50-Day Range
$26.10
$28.50
52-Week Range
$23.43
$29.77
Volume1,789 shs
Average Volume2,574 shs
Market Capitalization$8.48 million
P/E RatioN/A
Dividend Yield0.07%
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive LDRS News and Ratings via Email

Sign-up to receive the latest news and ratings for Innovator IBD ETF Leaders ETF and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer Innovator Capital Management
Fund NameInnovator IBD ETF Leaders ETF
Tax ClassificationRegulated Investment Company
SymbolNYSEARCA:LDRS
Inception Date12/21/2017
Fund ManagerDustin Lewellyn, Ernesto Tong, Anand Desai
WebN/A
PhoneN/A

Fund Focus

Asset ClassEquity
BenchmarkIBD ETF Leaders Index
CategoryStrategy
FocusAlpha-Seeking
Development LevelBlended Development
RegionGlobal

Fund Statistics

Assets Under Management$8.53 million
Average Daily Volume$746.30
Discount/Premium-0.02%

ETF Expenses

Management Fee0.60%
Other Expenses0.56%
Total Expenses1.16%
Fee Waiver0.00%
Net Expenses1.16%

Administrator, Advisor and Custodian

AdministratorU.S. Bancorp Fund Services, LLC
AdvisorInnovator Capital Management, LLC
CustodianU.S. Bank, N.A.
DistributorForeside Fund Services, LLC
Transfer AgentU.S. Bank, N.A.
Trustee
Lead Market MakerVirtu Financial

speech bubbles
speech bubbles











Innovator IBD ETF Leaders ETF (NYSEARCA:LDRS) Frequently Asked Questions

What stocks does MarketBeat like better than Innovator IBD ETF Leaders ETF?

Wall Street analysts have given Innovator IBD ETF Leaders ETF a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Innovator IBD ETF Leaders ETF wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Innovator IBD ETF Leaders ETF's stock price been impacted by COVID-19?

Innovator IBD ETF Leaders ETF's stock was trading at $19.63 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LDRS stock has increased by 44.0% and is now trading at $28.27.
View which stocks have been most impacted by COVID-19
.

Is Innovator IBD ETF Leaders ETF a good dividend stock?

Innovator IBD ETF Leaders ETF pays an annual dividend of $0.02 per share and currently has a dividend yield of 0.07%.
View Innovator IBD ETF Leaders ETF's dividend history.

What is Innovator IBD ETF Leaders ETF's stock symbol?

Innovator IBD ETF Leaders ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "LDRS."

Who are Innovator IBD ETF Leaders ETF's major shareholders?

Innovator IBD ETF Leaders ETF's stock is owned by many different institutional and retail investors. Top institutional shareholders include Susquehanna International Group LLP (10.30%).

Which institutional investors are buying Innovator IBD ETF Leaders ETF stock?

LDRS stock was purchased by a variety of institutional investors in the last quarter, including Susquehanna International Group LLP.

How do I buy shares of Innovator IBD ETF Leaders ETF?

Shares of LDRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Innovator IBD ETF Leaders ETF's stock price today?

One share of LDRS stock can currently be purchased for approximately $28.27.

How much money does Innovator IBD ETF Leaders ETF make?

Innovator IBD ETF Leaders ETF has a market capitalization of $8.48 million.


This page was last updated on 9/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.